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1. Introduction 
Angiotensin II is a polypeptide hormone possessing 
a potent contractile ffect on various mooth muscle 
cells [1]. Hormone-receptor interaction is the first 
event in the series of molecular processes leading to a 
hormonal effect on a target cell. Extensive investiga- 
tions performed uring the last decade have demon- 
strated that receptors for polypeptide hormones are 
located on the plasma membrane (for review, see [2]). 
Previous tudies from our laboratory have character- 
ized angiotensin II receptor sites of rabbit aortae 
plasma membranes [3]. In the present investigation, 
we report the principal properties of angiotensin II 
receptors of the plasma membrane of rat uterine 
myometrial cells which appear to be essentially 
similar to those of rabbit aorta smooth muscle cells. 
2. Methods 
Wistar female rats (weighing between 180 and 
200 g) were injected intramuscularly with 60/~g • 
100 tzg -~ diethylstilbestrol daily for 2 days before an 
experiment. They were killed by a blow on the head. 
Plasma membranes from myometrial smooth muscle 
were prepared according to the method of Kidwai 
et al. [4] with some modifications. The myometria 
from the uterine horns of 6 -8  rats were carefully 
separated from endometria, cut up finely with razor 
blades and homogenized with the use of an all-glass 
Potter-Elvehjem homogenizer for 1 min repeated two 
times at a speed of approximately 1400 rev/min. The 
homogenate (Hi) (in 0.25 M mannitol and 1 mM 
Tris-EDTA, pH 7.1) was centrifuged at 115 000 g 
for 40 min. The sediment [5] was resuspended in a 
minimum volume of buffer, layered on the top of a 
discontinuous gradient (2 ml 33% sucrose (d 1.14) 
below and 1 ml 8% sucrose (d 1.08) above) and 
centrifuged at 115 000 g for 90 min. The plasma 
membrane fraction (P), being the least dense com- 
ponent, was concentrated atthe interphase d 1.08/ 
1.14 and the rest of the homogenate (H2) (d > 1.14) 
representing mitochondria, endoplasmic reticulum 
and nuclei, sedimented. The plasma membrane 
fraction thus obtained was removed by aspiration 
and centrifuged at 115 000g for 40 min in 10 mM 
Tris-HC1 buffer, pH 7.4. 5'Nucleotidase measured 
according to Song and Bodansky [5] and adenyl- 
cyclase activity determined using the method of 
Krishna et al. [6], were considered as plasma 
membrane marker enzymes. As detailed in a previous 
publication [7], the specific activity of 5'Nucleotidase 
was 6 times higher in the plasma membrane fraction 
(P) than in the whole homogenate H1. The specific 
activity of adenylcyclase was augmented in a similar 
fashion: the basal and isoproterenol (10 -5 M) and 
NaF-stimulated activities all being 2-3 times higher 
in the membrane preparation (P) than in the whole 
homogenate H1. 
The binding of angiotensin II to membranes was 
studied within 4 hr of preparation of the membranes, 
the membranes being kept at 0°C, with the use of 
tritiated (Asn 1 , Val s )-angiotensin II retaining the 
full biological activity of the unlabelled hormone [8]. 
Two batches of [3 H] angiotensin II with specific 
activities of 39 and 70 Ci • mmole -1 respectively, 
were used. The incubation medium contained 
100 mM KC1, 5 mM MgC12 and 10 mM histidine 
buffer, pH 6.8, in a volume of 0.5 ml. The concentra- 
tion of membrane protein in the incubation medium, 
determined by the method of Lowry et al. [9] was 
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50-100/ lg -  m1-1 . Incubation was performed at 
29°C, after which membrane-bound and unbound 
radioactivity were separated by filtration on Millipore 
filters HAWP 0.45/am as described in previous 
publications [3]. Binding studies were performed in 
the presence and absence of 1000-fold excess of 
unlabelled angiotensin II; specific binding was con- 
sidered, according to the currently accepted proce- 
dure, as the difference between the radioactivity 
bound to membranes in the absence and in the 
presence of non-radioactive angiotensin. 
3. Results 
The time-course of the specific [3 HI angiotensin II 
binding to various myometrial subcellular fractions is 
represented in fig. 1. The concentration of angiotensin 
binding sites varied from one preparation to another, 
possibly in relation to the homogenization procedure, 
and was 7-20-fo ld higher in plasma membrane than 
in whole uterine homogenate Hi .  The enrichment of 
angiotensin binding sites in a purified plasma mem- 
brane fraction appears thus to be even higher than 
that of the two marker-enzymes adenylcyclase and 
5'nucleotidase. This result strongly suggests that 
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Fig.1. Specific displacable binding of 5 X 10 4 M angiotensin 
II on subcellular extracts from rat myometrium. P, S, H 2 and 
H~ represent various ubcellular f actions as described in the 
methods. P corresponds to the plasma membrane enriched 
fraction. The incubation was performed at 29°C and the 
binding expressed in cpm per mg of protein. 
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Fig.2. Uptake of 5 × 10 -8 M [3 Hlangiotensin I1 at 29°C by 
plasma membrane fraction, in the absence ( - - )  and presence 
( - - - )  of 5 × 10 -s M unlabelled angiotestin 11. Dissociation 
was followed as the exchange of bound [3 H]angiotestin with 
5 X 10 -s M unlabelled hormone added after five min of 
incubation. Each point is a mean value from five independent 
determinations. The vertical bar represents he standard error 
of the mean. 
angiotensin receptor sites are located in the plasma 
~nembrane and indicates that angiotensin receptors, 
as other peptide hormone receptors [10], may be 
considered as useful markers for this membrane 
fraction. 
The [3 H] angiotensin II binding to uterine 
membranes was not modified by preincubation of the 
membranes at 29°C in the incubation medium, (aL 
least) for up to 75 min. At 29°C, the specific binding 
of 5 × 10 -8 M [3 H] angiotensin II to the plasma 
membrane fraction reached equilibrium within 
5 -6  min (fig.2). The equilibrium of [3 H] angiotensin 
II binding was maintained at least up to 25 min, 
suggesting the absence of marked inactivation of the 
ligand during this period of time. 
Reversibility of the angiotensin binding was 
demonstrated by the addition of 1000-fold unlabelled 
angiotensin which resulted in a complete dissociation 
of the specific binding of 5 × 10 -s M [3 HI angio- 
tensin II within 15 min at 29°C (fig.2). Analysis of 
kinetic studies represented in fig.3 indicated an 
association rate constant K1 of 1.6 X 10 -s M -1 • 
sec -~ and a dissociation rate constant K_~ of 
1.3 × 10 -a • sec -1. 
The concentration dependence of angiotensin 
binding studied with [3 HI angiotensin concentration 
ranging from 5 X 10 -9 M to 5 × 10 -7 M indicated 
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Fig.3. Determination of rate constants by analysis of the 
association and dissociation kinetic studies. [3 H ] angiotestin 
II concentration was 5 × 10 -a M and the temperature of
incubation was 29°C. [RH] = concentration of the complex 
hormone-receptor at agiven time. lRHeq] = concentration f 
the hormone complex at equilibrium. [RHo] = concentration 
of the complex at the time 0 of the dissociation studies. 
the presence of two classes of binding sites (fig.4). 
The high affinity binding sites were saturated at a 
[3H] angiotensin II concentration of 10-7 M. According 
to the Scatchard plot [11], the high affinity binding 
sites have an apparent dissociation constant K d 
29°C value of 2 × 10 -~ M and a binding capacity of 
0.7 pmole • mg -1 protein. The low affinity binding 
sites appeared to be not saturated at a [a H] angio- 
tensin II concentration of 5 X 10 -7 M. The K d value 
estimated by the Scatchard plot (2 × 10 -~ M) is 
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Fig.4. Scatchard analysis of steady state specific binding data 
at 29°C for plasma membrane fraction with concentrations of
[3H]angiotensin II from 5 X 10 -9 M to 5 × 10 -7 M. 
close to theK d value of 8.3 × ]0 -9 M, calculated 
K_I 
from the ratio - -  
Kl 
The specificity of [3 H]angiotensin II binding 
was demonstrated by the inhibitory effect of various 
compounds added at a concentration of l0 -6 M on 
the binding of 5 × 10 -a M [a H]angiotensin II. 
Results are shown in table 1. Substitution of valine 
by isoleucine in position 5 did not affect the dis- 
placement. The 2 -8  angiotensin and 3 -8  angiotensin 
fragments displaced the octapeptide strongly. The 
inhibitory effect of the competitive antagonist Sat 1 , 
Ile s-angiotensin II was greater than that of the two 
other competitive inhibitors Alaa and lle 8-angio- 
tensin II. The decapeptide angiotensin I, which is the 
angiotensin II precursor [1 ], had no inhibitory effect, 
demonstrating that angiotensin I does not interact 
with angiotensin II receptors and that angiotensin I 
is not converted into angiotensin II by uterine mem- 
brane converting-enzyme during the period of incuba- 
tion. L-Noradrenaline and prostaglandin F2a, two 
compounds possessing a myotropic activity but being 
structurally different from angiotensin II, did not 
affect its binding, demonstrating that they interact 
with receptors different from those of angiotensin II. 
4. Discussion 
The demonstration of angiotensin specific binding 
sites in plasma membrane was not unexpectedly given 
the rapidity of the onset of-uterine contraction in 
response to angiotensin II and the various membrane 
phenomena elicited by the hormone, such as 
membrane depolarization [ 12], intracellular penetra- 
tion of extracellular calcium [ 13] and inhibition of 
adenylcyclase when this enzyme was previously stim- 
ulated by isoproterenol [14]. 
The identity of the plasma membrane binding 
sites to the receptors initiating the angiotensin 
contractile response is supported by various arguments. 
The first one is the rapidity of [3 H] angiotensin II
binding to plasma membrane, which occurs in a period 
of time very close to that necessary to obtain a 
maximal contraction. The second argument is the 
similarity of the concentration of angiotensin 
inducing half-maximal contraction (EDso) and that 
responsible for half-occupation of high affinity bin- 
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Table 1 
Inhibitory effect on [3 H]angiotensin II binding (%) 
aNH2 - Asp - Arg - Val - Tyr - Val - His - Pro - Phe 
a __  lie 
Oar Ile 
- -  lie 
Ala 
H is -  Leu 
100 
104 
106 
81 
68 
40 
41 
3 
L-Noradrenaline 2 
PGF 2 a 0 
a Angiotensin II 
b Angiotensin I. 
Inhibitory effect of angiotensins, angiotensin analogues and fragments, L-Noradrenaline and PGF~ a on 
5 X I0 -s M[ 3 HI angiotensin II binding to plasma membrane fraction d < 1.14. Labelled hormone and 
the other drugs (10 -4 M) were added simultaneously, and the incubation was performed at 29°C for 
5 min. The displacement of [3 H] angiotensin II by Asn I , Val 5-angiotensin II was considered as 100%. 
Each value is the mean of 4-8 determinations. 
ding sites (apparent dissociation constant or K d value). 
The EDso of the angiotensin dose-response curve on 
oestrogen pretreated uteri was reported to be 
1.0 + 0.1 X 10- a M [15] which is very close to the 
K d value of 2 × 10 -8 M reported here. Similarly, the 
angiotensin concentration responsible for the 
maximal contraction (2 X 10-7 M) is almost identical 
to the [3 H] angiotensin II concentration of 10-7 M 
which saturates the high affinity binding sites. 
The angiotensin-elicited contraction of uterine 
muscle is probably not a linear function of receptor- 
occupancy. The main reason is that angiotensin 
contraction is partially mediated by endogenous 
prostaglandins whose suppression changes both the 
EDs0 and the angiotensin concentration i ducing a 
maximal contraction [16]. The non linearity between 
receptor occupancy and contraction may be the 
explanation for the slight difference observed between 
the EDso and the K d values. It may also provide an 
explanation for another difference observed between 
the binding and the biological effect. The inhibitory 
effect of angiotensin fragments and analogues, as deter- 
mined in our experimental conditions, reflects the 
affinity of these compounds to receptors. The affinity 
of the 3 -8  hexapeptide for receptor site is higher 
than that suggested by the analysis of its contractile 
effect: the inhibitory effect of this compound on 
[a H] angiotensin II binding is 81% of that of unlabelled 
angiotensin, whereas its EDs0 value of 2.2 × 10- 6 M 
is more than 100 times higher than that of angiotensin 
II [17]. It would be extremely important o determine 
what factor contributing to the contraction is less 
sensitive to the hexapeptide than to the octapeptide 
angiotensin II, and particularly to know whether this 
difference stems from a difference in the stimulatory 
effect on endogenous prostaglandins. 
The present investigation shows that uterine mem- 
brane receptor sites are similar to those of rabbit 
aorta membrane [3,18] in the sense that these recep- 
tors interact with the C-terminal end of the angioten- 
sin molecule. This is clearly demonstrated by the 
fact that angiotensin fragments devoid of the first or 
the first two amino-acid residues are able to interact 
with angiotensin receptors in a way very similar to the 
intact octapeptide. If the N-terminal end of  the 
angiotensin molecule, although necessary for a com- 
plete biological effect, is not involved in the binding 
process to the receptor site, one may suggest hat the 
N-terminal end of angiotensin i teracts with a mem- 
brane component distinct from the binding site 
demonstrated in the present experiment. Angiotensin 
binding sites in bovine adrenal cortex seem to be 
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somewhat different, as their affinity for the 3 -8  
angiotensin II fragment is less important han that of 
smooth muscle cell receptors [20]. Prostaglandins 
not only mediate partially the contractile ffect of 
angiotensin II on rat uterus as previously mentioned, 
but also have a long-lasting potentiating effect on 
angiotensin action [17]. The lack of effect of prosta- 
glandins on [3H] anglotensin binding demonstrates 
that their potentiating effect on angiotensin does not 
involve a modification of the angiotensin-receptor 
mechanism, at least on oestrogen-pretreated rat uteri. 
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